Trial Profile

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
Indications Acral lentiginous melanoma; Malignant melanoma; Skin cancer; Uveal melanoma
Focus Therapeutic Use

04 Jun 2024 Results (n=26) assessing gene expression signatures analysis from BL and longitudinal tumor tissues and correlations with outcomes presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Pooled analysis result of NCT02231775 and NCT02519322 trial assessing relapse free survival at 3 years by pathological response to neoadjuvant systemic treatment in patients with surgically resectable, high-risk melanoma (n=97) presented at the 48th European Society for Medical Oncology Congress.
06 Feb 2023 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com